This is going to be challenging year in the US market: Glenn Saldanha

This is going to be challenging year in the US market: Glenn Saldanha As the chairman and managing director of Glenmark Pharmaceuticals, Glenn Saldanha oversees a fast-growing organisation that spans from an India-focused branded generics business to a significant export market across major emerging and developed economies. Glenmark’s branded generics presence is spread across five regions – Asia including India, Central Eastern Europe, Africa, Latin America and CIS. In less than five years, Glenmark has established itself among the top 25 generics companies in the US and also built a sizeable API business (active pharmaceutical ingredients) in a short span. Read More


Accord priority status to pharma and healthcare: Glenn Saldanha

Accord priority status to pharma and healthcare: Glenn Saldanha ‘Implement favourable policies to enhance innovation’ Glenn Saldanha, CMD, Glenmark Pharmaceuticals, has asked the government to substantially increase its spend on the healthcare and reform the public health system. “The government should make universal healthcare a priority and create a road map for ensuring quality, affordability and accessibility of medicines and treatment to the patients at all times,” says Saldanha in an interview with Soumonty Kanungo. What are your expectations for the pharma and healthcare sectors from the budget? For long, the budget has been a non-event for the pharma sector Read More


ˆ Back To Top